Evidence map›Paper›PMID 35775112›Full record

ArticleJournal of cellular and molecular medicine2022

ANKRD49 promotes the invasion and metastasis of lung adenocarcinoma via a P38/ATF-2 signalling pathway.

Yue-Hua Liu, Meng Yuan, Bai-Xue Xu, Rui Gao, Yu-Jie You, Zhi-Xin Wang, Yong-Cai Zhang, Min Guo, Zhao-Yang Chen, Bao-Feng Yu and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Corrigendum.Journal of cellular and molecular medicine · 2022
    Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yue-Hua LiuSchool of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
Meng YuanSchool of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
Bai-Xue XuSchool of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
Rui GaoDepartment of Pulmonary and Critical Care Medicine, The First Hospital, Shanxi Medical University; Shanxi Province Key Laboratory of Respiratory Disease, Taiyuan, China.
Yu-Jie YouSchool of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
Zhi-Xin WangSchool of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
Yong-Cai ZhangDepartment of Cardiothoracic Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.
Min GuoLaboratory of Animal Center, Shanxi Key Laboratory of Experimental Animal Science and Animal Model of Human Disease, Shanxi Medical University, Taiyuan, China.
Zhao-Yang ChenLaboratory of Animal Center, Shanxi Key Laboratory of Experimental Animal Science and Animal Model of Human Disease, Shanxi Medical University, Taiyuan, China.
Bao-Feng YuSchool of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
Qi-Wei WangClass ZT011907, The First Clinical Medical College, Shanxi Medical University, Jinzhong, China.
Hai-Long WangSchool of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.ORCID 0000-0001-9869-225X
Min PangDepartment of Pulmonary and Critical Care Medicine, The First Hospital, Shanxi Medical University; Shanxi Province Key Laboratory of Respiratory Disease, Taiyuan, China.
Shanxi Medical University · CN

Funding

The Advanced Program for Returned Scholars of Shanxi Province Science and Technology Activities 2019-1176The Natural Science Fund of Shanxi Province 201901D111352The Research Project Supported by Shanxi Scholarship Council of China HGKY2019056The Science and Technology Cooperation and Exchange Special Project of Shanxi Province 202104041101012
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most challenging neoplasm to treat in clinical practice. Ankyrin repeat domain 49 protein (ANKRD49) is highly expressed in several carcinomas; however, its pattern of expression and role in LUAD are not known. Tissue microarrays, immunohistochemistry, χ

Indexed as

Adenocarcinoma of LungLung NeoplasmsActivating Transcription Factor 2AnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticMatrix Metalloproteinase 9MiceMice, NudeMuscle ProteinsSignal TransductionActivating Transcription Factor 2ankyrin repeat domain 49 protein, mouseAtf2 protein, mouseMatrix Metalloproteinase 9Muscle ProteinsANKRD49ATF-2lung adenocarcinomamatrix metalloproteinasesP38/MAPK

Identifiers

PMID35775112
PMCPMC9357638
OpenAlexW4283756029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.